In Vivo Activity Articles & Analysis
15 news found
Data support the potential of INB-100 to induce long-term durable responses in patients with high-risk or relapsed acute myeloid leukemia (AML). Clinical activity observed includes continuing robust durability of relapse-free survival; all three patients in Cohort 1 remain alive and progression-free; ongoing durations of response exceed 12 months and extend beyond 25 months. ...
Patient Characteristics*: About the INB-100 Phase 1 Trial The Phase 1 clinical trial (NCT03533816) is a dose-escalation trial of allogeneic derived, gamma-delta T cells from matched related donors that have been expanded and activated ex vivo and administered systemically to patients with leukemia following haploidentical HSCT. ...
Preclinical data has shown it has potent activities in vitro and in vivo against SARS-CoV-2 variants such as Alpha, Beta, Delta, and Omicron. ...
AFM28 induced potent, effective, and specific anti-tumor activity against CD123-positive cells irrespective of mutational status Study demonstrated specific anti-tumor response even at low levels of CD123 expression with no evidence for off-target cytotoxic activity towards CD123-negative healthy bone marrow progenitors In vivo studies of an ...
Enrollment continues in the phase 1/2a combination study of AFM24 with the SNK01 (ex vivo expanded and activated autologous NK cell therapy from NKGen Biotech) cells (AFM24-103) to treat patients with non-small cell lung cancer (NSCLC, EGFR-wildtype), squamous cell carcinoma of the head and neck, and colorectal cancer. ...
Preclinical studies showed AFM24 induced killing of EGFR+ tumor cell lines independent of EGFR expression level and independent of mutations in the EGFR signaling pathway. In vivo studies in cynomolgus monkeys demonstrated a favourable safety profile. ...
Calibrated release interleukin-15: The crIL-15 construct is designed to simultaneously produce both membrane-associated and fully secreted IL-15, to enable both autocrine cytokine signaling (to increase CAR-NK cell proliferation and persistence) and paracrine cytokine signaling (to stimulate the patient's surrounding immune cells). New in vivo CAR-NK cell ...
Preclinical data has shown it has potent activities in vitro and in vivo against SARS-CoV-2 variants such as Alpha, Beta, Delta, and Omicron. ...
PAD4 inhibition a novel pathway to inhibit tumor metastasis and tumor growth Data presented at the American Association of Cancer Research Annual Meeting 2022 Jubilant Therapeutics Inc. a biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced data to be presented at the American ...
The results indicate superior tumor killing and persistence of CAR-NK cells as well as optimal activation of other anti-tumor immune cells. The authors' preclinical research illustrates the benefits of Senti Bio’s calibrated release gene circuit technology to improve CAR-NK cell functions aimed at enhancing solid tumor killing. The poster, titled “Driving anti-tumor ...
Stephen Neidle Session Title: Structural and Chemical Biology Session Date and Time: Tuesday Apr 12, 2022 9:00 AM - 12:30 PM CDT Abstract Number: 4069 Title: “The potent quadruplex-binding compound SOP1812 shows anti-tumor activity in patient-derived in vivo models of pancreatic cancer” Lead Author: ...
In vivo data presented at the SITC annual meeting highlight the potential of T-knife’s lead product candidate TK-8001, a TCR engineered T cell therapy (TCR-T) that is being developed to treat MAGE-A1 positive solid tumors. ...
The selected ADCs will be evaluated on its anti-tumour activity in in vitro and in vivo systems and will then be considered for IND-enabling studies. ...
Adenosine has an immune-suppressive effect in tumors, and pre-clinical and early clinical evidence indicates that antagonists of the GPCR family of adenosine receptors are able to relieve that suppression and restore anti-tumor immune cell activity. EXS21546 is a non-furan, selective antagonist of the A2A receptor with low brain penetration. Using EXS21546, we show that ...
The advancement of ART24 into the Phase 1 clinical trial was based on its favorable profile exhibited in pre-clinical safety testing, as well as its demonstration of potent and selective in vitro and in vivo activity against C. difficile and associated toxins. The Phase 1 clinical trial is evaluating ART24 for safety, tolerability and pharmacokinetics in a ...